NCT02307487View on ClinicalTrials.gov

Safety of Pre-TURBT Intravesical Instillation of Escalating Doses of TC-3 Gel and MMC in NMIBC Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

April 30, 2016

Study Completion Date

June 30, 2017

Conditions
Bladder CancerNeoplasmsUrinary Bladder DiseasesUrologic Diseases
Interventions
DRUG

120 mg MMC in 90ml gel

120 mg of Mitomycin C mixed with 90 ml UroGen's TC-3 gel

DRUG

140 mg MMC in 90ml gel

140 mg of Mitomycin C mixed with 90 ml UroGen's TC-3 gel

DRUG

160 mg MMC in 90ml gel

160 mg of Mitomycin C mixed with 90 ml UroGen's TC-3 gel

DRUG

120 mg MMC in 60ml gel

120 mg of Mitomycin C mixed with 60 ml UroGen's TC-3 gel

DRUG

140 mg MMC in 60ml gel

140 mg of Mitomycin C mixed with 60 ml UroGen's TC-3 gel

DRUG

160 mg MMC in 60ml gel

160 mg of Mitomycin C mixed with 60 ml UroGen's TC-3 gel

Trial Locations (2)

Unknown

Wolfson Medical Center of Holon, Department of Urology, Holon

Meir Medical Center, Kfar Saba

All Listed Sponsors
lead

UroGen Pharma Ltd.

INDUSTRY

NCT02307487 - Safety of Pre-TURBT Intravesical Instillation of Escalating Doses of TC-3 Gel and MMC in NMIBC Patients | Biotech Hunter | Biotech Hunter